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This study was conducted to assess the effect of carbamazepine, sodium valproate and
phenytoin on serum liver enzymes in 49 epileptic patients admitted to the neurology
outpatient clinic at Beni-Suef University between February 2010 and June 2011. The pa-
tients were separated into group I (16 patients) treated with 200e1200 mg/day carbamaz-
epine; group II (16 patients) treated with 200e800 mg/day sodium valproate; and group III
(17 patients) treated with 200e400 mg/day phenytoin. Serum liver enzymes aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and
serum level of antiepileptic drug were determined. No patient developed clinical symptoms
of liver disease. Hepatic enzymes abnormal values were seen in 51.9% (n ¼ 27) in the three
study groups. In group I, the alterations at ALP enzyme were 50% (n ¼ 8). In group II, the
alterations at ALT were 6.25% (n ¼ 1) and at ALP were 62.5% (n ¼ 10). In group III, the al-
terations at AST were 5.88% (n ¼ 1), at ALT were 17.65% (n ¼ 3) and at ALP were 23.53%
(n ¼ 4). There was a statistically significant positive correlation between the dose/kg of
carbamazepine and the serum level of the drug, a statistically significant positive corre-
lation between the dose/kg of sodium valproate and AST and a statistically significant
negative correlation between the duration of administration of sodium valproate and AST.
There was also a statistically significant negative correlation between the duration of
administration of carbamazepine and AST and ALP. In conclusion, sodium valproate was
more hepatotoxic than carbamazepine which was more hepatotoxic than phenytoin. The
routine screening of hepatic enzymes level during the chronic use of antiepileptic drugs is
recommended.
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b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 3 ) 1 4e1 9 151. Introduction included 16 epileptic patients on carbamazepine medicationEpilepsy is not a disease, but a syndrome of different cerebral
disorders of the Central Nervous System (CNS) which is
characterized by excessive discharges of large numbers of
neurons (Nikalje et al., 2011). It is very disabling condition,
rendered especially disturbing because of its unpredictability
and its being a common neurological disorder worldwide
(Ahmad, 2011).
The liver is the primary organ for drug metabolism and
elimination for many antiepileptic drugs (AEDs) and thus is
subjected to drug-induced toxicity. There is a wide range of
hepatotoxic reactions, from mild and transient elevations of
hepatic enzymes to fatal hepatic failure (Arroyo and de la
Morena, 2001).
Liver enzymes can serve as markers of hepatocellular
injury e.g. aspartate aminotransferase (AST), alanine amino-
transferase (ALT) or of an obstruction in the bile flow chole-
stasis e.g. alkaline phosphatase (ALP) and gamma-glutamyl
transferase (GGT). Although these enzymes are elevated in
liver disease, the elevation can also be secondary to enzyme
induction without hepatic pathology (Ahmed and Siddiqi,
2006). In particular, antiepileptic drugs have many serious
reactions, as seen with carbamazepine (CBZ), valproic acid
(VPA) and phenytoin (PHT). Though relatively rare, when
compared with other consistently known hepatotoxic drugs,
the hepatotoxicity induced by antiepileptic drug can lead to
death or an acute liver failure which could imperatively
require liver transplantation. The hepatotoxicity induced by
antiepileptic drug occurs either because of production of
reactive toxic metabolite/s or because of induction of immu-
noallergic reactions (Lee, 2003; Bjornsson, 2008). Such AEDs
(CBZ, PHT and VPA) are associated with mild elevations of
liver enzymes, which may occur in up to 50% of patients.
These elevations are usually transitory or dose-related and do
not appear to be associated with hepatocellular injury.
Usually, hepatotoxicity is associated with other clinical
manifestations of drug allergy (fever, rash and eosinophilia).
This reaction is typical of CBZ and PHT. Another idiosyncratic
hepatotoxic reaction comes from hepatotoxic metabolites
because of aberrant metabolism. This reaction has been
observed with VPA (Arroyo and de la Morena, 2001).
A more than two to threefold increase in liver enzymes
during AED therapy should caution the physician of a poten-
tial of coexistent liver disease. If subsequent follow-up reveals
a progressive increase in the values of the enzymes, in-
vestigations for coexistent liver disease are warranted and
may require a switch to an alternative AED (Ahmed and
Siddiqi, 2006). Therefore the aim of the present work was to
study the effect of antiepileptic drugs on liver enzymes.2. Subjects and methods
2.1. Subjects
This study was conducted on 49 subjects selected from
outpatient clinics at Beni-Suef University Hospital. In this
cross-sectional study, therewere 3 groups of patients:Group I:with daily dose ranging from 200 to 1200 mg. Group II:
included 16 epileptic patients on sodiumvalproatemedication
with daily dose ranging from200 to 800mg.Group III: included
17 epileptic patients on phenytoin medication with daily dose
ranging from 200 to 600 mg.2.2. Inclusion criteria
The study included epileptic patients receiving one of the
following antiepileptic drugs (carbamazepine, sodium val-
proate or phenytoin) from at least 6 months.2.3. Exclusion criteria
Epileptic patients who had concomitant liver diseases, using
other drugs causing elevation of liver enzymes (e.g. antibi-
otics, anti-rheumatic drugs, statins and nonsteroidal anti-
inflammatory drugs) or those who were alcohol drinkers
were excluded from the present study.2.4. Through clinical assessment
Subjects included in this study were subjected to careful his-
tory taking, general and neurological examination “according
to standardized neurological sheet” including the name, age,
gender, weight of each epileptic patient, the duration of
therapy and the daily dose of antiepileptic drug.2.5. Laboratory work up
All subjects included in this study were subjected after two
hours of the antiepileptic drug’s administration to the
following laboratory investigations:
1) Serum liver enzymes including:
a) Alanine aminotransferase (ALT) which has a reference
range of 10e55 U.
b) Aspartate aminotransferase (AST) which has a refer-
ence range of 10e40 U/L.
c) Alkaline phosphatase (ALP) which has a reference
range of 45e115 U/L.
2) Serum level of the antiepileptic drug.
a) Carbamazepine serum level which has a reference
range of 4e12 mg/ml.
b) Sodium valproate serum level which has a reference
range of 50e100 mg/ml.
c) Phenytoin serum level which has a reference range of
10e20 mg/ml.
According to the reference range of either the antiepi-
leptic drug’s serum level or the liver enzymes serum level,
the epileptic patients in each study group were classified
into those with normal and those with abnormal serum
level. Finally, the abnormal values of serum liver enzymes of
each antiepileptic drug were compared with each other to
rank these antiepileptic drugs according to their
hepatotoxicity.
Table 1 e The serum level of the antiepileptic drugs in
study groups.
Serum level
of the drugs
in mg/ml
Mean  SD Normal
N (%)
Abnormal
N (%)
Elevated
N (%)
Group I 5.7  4.7 7(43.75) 9(56.25) 2(12.5)
Group II 40.2  30.0 4(25) 12(75) 1(6.25)
Group III 6.2  5.9 2(12.5) 15(88.24) 1(5.88)
Table 3 e Correlation between the duration of drug
administration and liver enzymes.
Liver
enzymes
in U/L
Duration of drug administration in years
Group I Group II Group III
(r) Coef. p (r) Coef. p (r) Coef. p
AST 0.5 0.048* 0.4 0.027* 0.1 0.484
ALT 0.1 0.735 0.1 0.739 0.2 0.424
ALP 0.4 0.029* 0.4 0.084 0.2 0.401
(r) Using Pearson coefficient of correlation, p > 0.05 (non-signifi-
cant), and *p < 0.05 (significant).
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Forty nine patients (22 females) completed the study in the
three groups, 16 (7 females) in group I, 16 (8 females) in group II
and 17 (7 females) in group III. The mean  SD age of the
epileptic patients in the three groups were 17.8  14.4,
14.8  10.5 and 31.8  10.4, respectively. The serum level of
antiepileptic drug in the three study groups is shown in Table
1. The abnormal and normal values of liver enzymes for the
epileptic patients in the three study groups are shown in Table
2. There was a statistically significant difference between the
three study groups as regards the mean values of ALP
(p ¼ 0.020), but there was no statistically significant difference
between the study groups as regards the mean values of AST
(p ¼ 0.410) or ALT (p ¼ 0.327).
The results of the correlation between the duration of drug
administration in years and liver enzymes are shown in Table
3 and Figs. 1e5. In group I, there was a statistically significant
negative correlation between the duration of administration
of carbamazepine and AST (r coefficient ¼ 0.5, p ¼ 0.048) as
shown in Fig. 1. There was no significant correlation between
the duration of drug administration and liver enzymes except
between the AST and carbamazepine and sodium valproate
and between ALP and carbamazepine as shown in Figs. 1e3.
The correlations were all negative correlation with correlation
coefficient (r) ¼ 0.5, 0.4 and 0.4 respectively and p ¼ 0.048,
0.027 and 0.029, respectively.
There was no statistically significant correlation between
the duration of drug administration in years and the serum
level of drug. Moreover, there was no statistically significant
correlation between liver enzymes and the serum level of
drug.
In group II, a statistically significant positive correlation
between dose/kg of group II (sodium valproate) and AST
(r coefficient ¼ 0.7, p ¼ 0.004) as shown in Fig. 4. However, in
groups I and III, there was no statistically significant corre-
lation between dose/kg of the drug and any of the liver
enzymes.Table 2 e Serum level of the liver enzymes in study groups.
Liver enzymes
in U/L
Group I
Abnormal N (%) Normal N (%) Abnorma
AST 0(0) 16(100) 0(0)
ALT 0(0) 16(100) 1(6.2
ALP 8(50) 8(50) 10(62In group I, there was a statistically significant positive
correlation between dose/kg of carbamazepine and Serum
level of drug (r coefficient ¼ 0.6, p ¼ 0.010) as shown in Fig. 5,
but in groups II and III, there was no statistically significant
correlation between dose/kg of the drug and the serum level of
drug.4. Discussion
The present study was conducted on 49 epileptic patients; 16
patients using carbamazepine, 16 patients using sodium val-
proate and 17 patients using phenytoin. All patients were
submitted to through history, medical and neurological ex-
amination, measurement of serum liver enzymes and serum
level of antiepileptic drug. Patients using carbamazepine had
significantly higher ALP than those using phenytoin, but there
was no statistically significant difference between the three
groups regarding AST or ALT. The results also revealed a
statistically significant negative correlation between the
duration of carbamazepine administration and AST & ALP.
In accordance with our results, (O’Hare et al., 1980)
demonstrated that there was a statistically significant corre-
lation between the duration of administration of carbamaze-
pine and ALP elevation. Christiansen (1982) and O’Hare et al.
(1980) attributed this effect on liver enzymes to enzyme
inducing property of carbamazepine leading to the induction
of microsomal hepatic enzymes. Controversially, Bjornsson
et al. (2007) reported there was no correlation between the
duration of therapy of carbamazepine and elevated liver
enzymes.
The results also show there was no statistically significant
correlation between the daily dose of carbamazepine and liver
enzymes. Similarly, Sillanpaa (1981) and Kalapos (2002) re-
ported the hepatotoxicity of carbamazepine is independent of
the daily dose. In contrast to our results Perucca et al. (2004)Group II Group III
l N (%) Normal N (%) Abnormal N (%) Normal N (%)
16(100) 1(5.88) 16(94.11)
5) 15(93.75) 3(17.64) 14(82.35)
.5) 6(37.5) 4(23.53) 13(76.47)
Fig. 1 e Correlation between the duration of
carbamazepine administration in years and AST in group I.
Fig. 3 e Correlation between the duration of
carbamazepine administration in years and ALP in group I.
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 3 ) 1 4e1 9 17provided the data demonstrating a dose-dependent degree of
enzyme induction in epileptic patients receiving therapeutic
doses of carbamazepine.
The results also revealed there was no statistically signifi-
cant correlation between the serum level of carbamazepine
and liver enzymes. Contrary to our results, Deda (1993) re-
ported a statistically significant positive relationship between
the serum level of carbamazepine and the serum ALP level.
Sonmez et al. (2006) illustrated that the discrepancy between
the results can be attributed to patients’ characteristics such
as age, gender and race; differences inmethods; and the study
protocol. Also, the doses of carbamazepine might have been
too low to cause significant elevations in liver enzymes levels.
Patients using sodium valproate have significantly higher
ALP than those using phenytoin, but there was no statistically
significant difference between the three groups regarding AST
or ALT. The results also revealed a statistically significant
positive correlation between the daily dose of sodium val-
proate and AST. In agreement with our study, Verma and
Haidukewych (1994) showed a statistically significant corre-
lation between the dose of valproic acid and AST. Moreover,
Spiller et al. (2000) reported that valproic acid mediated he-
patic injury is associated with dose dependent rise in serum
liver enzymes. Contrary to our results, Sussman (1979) noted
that valproic acid-associated hepatotoxicity is distinct from
the form of dose-related liver enzyme elevation that appearsFig. 2 e Correlation between the duration of sodium
valproate administration in years and AST in group II.to be reversible with a reduction in dosage or discontinuation
of the drug. Moreover, Felker et al. (2003) and Willmore et al.
(1978) demonstrated through retrospective studies a tran-
sient elevation of liver ALT and AST in epileptic patients on
valproic acid. On the other hand, Hauser et al. (1996) found
that these finding were not reproduced in a prospective study
with a relatively small sample size.
The results of our study also reported a statistically sig-
nificant negative correlation between the duration of sodium
valproate administration and AST. Contrary to our findings,
Huang et al. (2003) suggested that severe hepatotoxicity re-
action may be unrelated to the dose or duration of valproic
acid. Moreover, Huang et al. (2003) and Roma-Giannikou et al.
(1999) proved that there was no statistically significant cor-
relation between hepatotoxicity and the dose or duration of
valproic acid. Similarly, Hoshino et al. (1995) suggested that
there was no correlation between the elevations in ALT and
AST and the dose of valproic acid.
The results also indicated that there was no statistically
significant correlation between the serum level of sodium
valproate and liver enzymes.
Gopaul et al. (2003) and Sonmez et al. (2006) suggested that
the divergence in results may be due to variations in risk
factors of development of valproic acid induced hepatotoxic-
ity e.g. younger age, mental retardation, history of metabolic
disorders or inborn error of metabolism, polypharmacy,Fig. 4 e Correlation between AST and dose/kg of sodium
valproate in group II.
Fig. 5 e Correlation between the serum level of
carbamazepine and its dose/kg in group I.
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disease. In addition, Boelsterli and Lim (2007) have recently
proposed a unifying hypothesis that involves underlying ge-
netic or acquired mitochondrial abnormalities as a major
determinant of susceptibility to hepatotoxicity induced by
valproic acid.
Patients using phenytoin have significantly lower ALP than
those using carbamazepine or sodium valproate, but there
was no statistically significant difference between the three
groups regarding AST or ALT. Our results also revealed that
there was no statistically significant correlation between the
duration of phenytoin administration and liver enzymes, the
dose of phenytoin and liver enzymes or between the serum
level of phenytoin and liver enzymes. Similar to our findings,
Craig (2005) found that there was no statistically significant
correlation between serum level of phenytoin and the risk for
hepatotoxicity. Controversially, Perucca et al. (2004) suggested
a dose-dependent degree of enzyme induction in epileptic
patients receiving therapeutic doses of phenytoin. Similarly,
Spielberg et al. (1981) proved a dose dependant hepatotoxicity
of phenytoin. Moreover, Breckenridge (1973) and Ohnhaus
et al. (1983) confirmed a statistically significant positive cor-
relation between the dose of phenytoin and the serum liver
enzymes. Similarly, Meythaler (1998) reported a statistically
significant positive correlation between the dose of phenytoin
and the serum alkaline phosphatase.
Generally, Roy et al. (1993) suggested that chronic liver
enzyme abnormalities associated with phenytoin have been
attributed to enzyme induction. Similarly, Aiges et al. (1980)
found that the transient nature of the elevations of ALT and
AST, and the absence of specific histopathology during
chronic treatment with phenytoin does not result in hepato-
toxicity but rather in enzyme induction.
Walia et al. (2004) reported that hepatotoxicity of
phenytoin is an important side effect that has been brought to
attention. Bessmertny et al. (2001) described the hepatotox-
icity of phenytoin as antiepileptic hypersensitivity syndrome
requiring immediate discontinuation of the antiepileptic drug.
According to Bauer and Blouin (1982) and Mendis et al.
(1993) conflicting results may be due to the differences in
age and sex.
The present study indicated that patients using carba-
mazepine have significantly higher ALP than those usingphenytoin and patients using sodium valproate have
significantly higher ALP than those using phenytoin. We
also concluded that the more is the dose/kg of sodium val-
proate, the more is the elevation of AST, the more is the
dose/kg of carbamazepine and the more is the serum level
of carbamazepine. In addition, during the initiation of
antiepileptic drugs, the liver enzymes were elevated due to
the enzyme inducing property of some of them. That is
what happened during the first 6 months of the adminis-
tration of antiepileptic drug especially that our study was
conducted on epileptic patients taking the antiepileptic drug
from at least 6 months. But with time, the liver tests
can normalize despite continued therapy probably due
to adaptation in the liver. This idea was provided by
Bjornsson (2008). Consequently, this thought explains the
statistically significant negative correlation between the
duration of the antiepileptic drug administration and AST
and ALP.5. Conclusion and recommendations
Finally, our results showed that sodium valproate is more
hepatotoxic than carbamazepine which is more hepatotoxic
than phenytoin. Routine screening of hepatic enzymes level
during the chronic use of antiepileptic drugs is recom-
mended. The need for obtaining baseline liver function tests
is essential before starting antiepileptic therapy and regular
monitoring of serum aminotransferase values that had any of
the risk factors for liver damage during antiepileptic therapy.
Precautions should be taken when using antiepileptic drugs
in epileptic patients with pre-existing hepatic disorders, in
patients using potentially hepatotoxic drugs or if signs or
symptoms of hepatic impairment appear. Because little long-
term hepatic follow-up is available with antiepileptic treat-
ment, controlled studies in larger samples should be carried
out to reveal the frequency and the risk factors of serious
hepatotoxicity.
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